Dongguan Fama Biotechnology Co., Ltd. – Trademark Portfolio

Entity Type: 99

Dongguan Fama Biotechnology Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include FIAMR. The owner is based in Dongguan, Guangdong.

Shunlian Road, Wanjiang Street

Room 110, Building 7, No.10

Dongguan, Guangdong 523393 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

FIAMR
FIAMR
Registered 2024

Trademark Classifications

Dongguan Fama Biotechnology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

9
Computers & Electronics (1 filing)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

Frequently Asked Questions

How many trademarks does Dongguan Fama Biotechnology Co., Ltd. have?

Dongguan Fama Biotechnology Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Dongguan Fama Biotechnology Co., Ltd. file in?

Dongguan Fama Biotechnology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 9 (Computers & Electronics). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.

What are Dongguan Fama Biotechnology Co., Ltd.'s most well-known trademarks?

Dongguan Fama Biotechnology Co., Ltd.'s registered trademark portfolio includes well-known marks such as FIAMR. These are among 1 currently registered trademark in the portfolio.

What is Dongguan Fama Biotechnology Co., Ltd.'s trademark registration success rate?

Dongguan Fama Biotechnology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.